

# Standards and Procedures of HTA in China— The Role of Economic Evaluation

Mr. Haiyin Wang

**Division Director**

**Shanghai Health Development Research Center**



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心



1

**HTA Procedures- International Experiences**

2

**HTA Process in China**


3

**The Role and Adaption of HTA In China**

# HTA-Models



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心




Resources : Adrian Griffin, (2014) , HTA Forum in Shanghai materials



- ❑ Integrating HTA into Health and Social Act and relevant regulations
- ❑ Developing HTA guidelines and procedures
- ❑ Involving multi-stakeholders, and open to the public, in order to be transparency.



- The National Institute for Health and Care Excellence ( NICE ) integrates all relevant evidences for HTA, and plays an important role in designing clinical guideline and health insurance reimbursement Manual.
- In 2009, NICE released Single technology appraisal (STA ) and Multiple technology appraisal (MTA ) procedure guidelines. In 2014, NICE published an updated guides to the methods of technology appraisal, including, health technology procedures guideline, health technology methodology guidelines, a evaluation complaints etc.






Figure1. Summary of the STA process

- ❑ Australia mainly has Pharmaceutical Benefits Advisory Committee , (**PBAC** ) and Medical Services Advisory Committee (**MSAC** ) , HTA are directly use in the adaption of Drug and Medical Services Reimbursement and Payment Policy Planning
- ❑ Basically, procedures in Australia and NICE are the same, the applicants need to provide evidences to support their application, then the external experts will make a judgment for the project to be implemented.
- ❑ Differences: Australia is mainly assessed by consultants organized by one agency and academic community





Figure 2. Summary of PBAC process





**Figure 3. Summary of PBAC process**



1

**HTA Procedures- International Experiences**

2

**HTA Process in China**

3

**The Role and Adaption of HTA In China**



**Medical Service Items** ; pay for service,  
Medical Services Reference Price Catalog, MOH,  
Health Insurance Department , Price Bureau

➡ **Guidelines, Pricing  
Setting and  
Payment**

**Drug** : eliminated Majority Government Price  
Setting Mechanism , health Insurance Payment  
Standards , centralized / local Bidding Procurement,  
Essential Drug List

➡ **Guidelines, payment  
Standards**

**Medical Disposables Materials:** Transparency  
Procurement Model, Hospital, Health Insurance Department,  
MOH ( **Shenkang** ) , Price Bureau

➡ **Hospital Purchasing  
Catalog, Purchasing  
Prices**



## National and Local Organization

- Policy Makers and Payers ( Users )
- Policy Makers and Payers ( Initiator )
- Public And Health Insurance  
( Perspectives )
- Government ( national/Local )  
( Funding/Pool )

## Hospital

- Hospital administrator and clinical administrator ( Users )
- Physicians (Initiators )
- Hospitals (Perspectives )
- Other resources ( Funding )



## Four Steps

- Applying And Scoping Appraisal Topic
- Evidence Review Group
- Appraisal Committee Meeting
- Finalized and Adaption (Figure 4)

## Two Pathway

- **Applicants needs HTA and submits reviewing materials to get the technology been reviewed and evaluated by Health Technology Evaluation Organizations (similar to STA)**
- **Applicants providing materials, the Health Technology Evaluation Organization will evaluate the proposal (similar to MTA)**

❑ **Multi-stakeholders and transparency** Medical Technical Division  
From Pharmaceutical Company , HTA Research Center/ Organization and  
Relevant Health Regulators

# HTA-Process in China



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心





Figure 4. The Process of HTA in China



**Figure 5.** Shanghai HTA Center---the process of HTA

## Abstract

Agency provide abstract ; HTA report abstract

## Background

Disease Treatment ; evaluation technic, regulations

## Outcomes

Literature review from international studies ; Cochrane

## Economic Evaluation

Library, Medline literature review ; evidence-based evaluation based on the materials provided by agency ; outcomes and results

## Technical application impact assessment

population ; evaluation the burden of disease ; budget constraint analysis

## Conclusion/ Suggestions

Conclusion ; policy suggestion

## References

## Appendix





1

**HTA Procedures- International Experiences**

2

**HTA Designing Process in China**


3

**The Role and Adaption of HTA In China**

# HTA, EBM, CER?



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心



Notes:

RCT = randomized controlled trial

PCT = pragmatic clinical trial

SRT = systematic review of trials

SRE = systematic review of evidence

CER = comparative effectiveness research

HTA = health technology assessment

EBM = evidence-based medicine

CED = coverage with evidence development

Solid lines indicate clear relationships, and dotted lines indicate disputed relationships. Diamonds represent decision processes, and circles and ovals represent all other evidence activities, except for the rectangles, which are reserved for EBM, HTA, and CER.

FIGURE 2. Redefined Relationships of Evidence Processes.

# HTA-卫生经济评价应用思考



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心

indicator s	Scientific standards
Disease	The degree of severity
	Influenced population
Intervention background	Clinical guideline
	limits
Intervention results	Improvement in outcomes
	Improvement in safety
	Effective treatment by patient feedback
Benefit type	public health benefit
	Medical service type
Economic evaluation	Budget constraint
	CEA
	Other costs
Evidence-based	adherence
	The completeness and consistency of the report
	Linkage and effectiveness of the evidences

Information needed	US	Canada	England	Germany	Australia	Taiwan
Disease background	√	√	√	√	√	√
Product information	√	√	√	√	√	√
Clinical benefits (including patient benefits)	√	√	√	√	√	√
PE evidence	Plan specific	√	√	Optional	√	√
Comparative analysis	√	√	√	√	√	√

- For the same functional ( class ) drugs, we set cost-effectiveness analysis outcomes as priorities prerequisite based on the principle of the pharmaceutical economics.
- Based on the results of the HTA, we can get rid of the high cost and less effectiveness drugs from the drug lists.
- **In the Centralized procurement bidding system**, the drugs with relative better outcomes and less cost, will be more attractive and getting a relative higher bidding price than the less effectiveness one. At the same time, we are highly encourage the development of innovative drugs.
- We have developed one reimbursement payment system for the innovative drugs which were lacking of competitors, based on the results of HTA and

- **Medical Services Price Catalog** , DRG ; Price of Services Items.
- The Selection of Technology, Evaluation and Adaptation
- The Development of Clinical Practices Guidelines.
- Re-evaluation and Adjustment on a regular basis for the limitations of Clinical Health Technology Application



- Procurement(purchase of Hospital High Value Disposable Materials and Price Negotiation Mechanism
- Low-value and One-time Used Disposable Materials Packaging Selection

# Thank you



上海市医学科学技术情报研究所  
上海市卫生技术评估研究中心